<code id='AB501BB23D'></code><style id='AB501BB23D'></style>
    • <acronym id='AB501BB23D'></acronym>
      <center id='AB501BB23D'><center id='AB501BB23D'><tfoot id='AB501BB23D'></tfoot></center><abbr id='AB501BB23D'><dir id='AB501BB23D'><tfoot id='AB501BB23D'></tfoot><noframes id='AB501BB23D'>

    • <optgroup id='AB501BB23D'><strike id='AB501BB23D'><sup id='AB501BB23D'></sup></strike><code id='AB501BB23D'></code></optgroup>
        1. <b id='AB501BB23D'><label id='AB501BB23D'><select id='AB501BB23D'><dt id='AB501BB23D'><span id='AB501BB23D'></span></dt></select></label></b><u id='AB501BB23D'></u>
          <i id='AB501BB23D'><strike id='AB501BB23D'><tt id='AB501BB23D'><pre id='AB501BB23D'></pre></tt></strike></i>

          Home / hotspot / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:596

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In